Biomimetic nanovesicle vaccines derived from dendritic cells sensitized with whole tumor antigens for melanoma immunotherapy
This study introduces a novel vaccination strategy utilizing the DC-derived nanovesicle vaccine, diA-MADCVac. Systematic studies and experimental validation demonstrate that diA-MADCVac exhibits excellent biocompatibility, ensuring its safety for <i>in vivo</i> use. This nanovesicle serves as an effective carrier, efficiently delivering both adjuvants and antigens to lymph nodes, thereby enhancing DC-mediated anti-tumor immune responses. Additionally, diA-MADCVac promotes trained immunity and enhances the tumor-killing capacity of immune cells. With its unique advantages, diA-MADCVac offers an efficient, safe, and promising new approach for tumor treatment, providing renewed hope for cancer patients.
Authors
- Zongguang Tai (ORCID: https://orcid.org/0000-0001-5603-745X)
- Fengze Miao (ORCID: https://orcid.org/0000-0003-1360-2935)
- Quangang Zhu (ORCID: https://orcid.org/0000-0002-0574-4020)
- Ruyi Wang (ORCID: https://orcid.org/0000-0001-5832-5391)
- Yingchao Zhao (ORCID: https://orcid.org/0000-0002-1979-2816)
- Zhongjian Chen (ORCID: https://orcid.org/0000-0003-3789-7096)
- Jun Liu (ORCID: https://orcid.org/0000-0003-4800-7749)
- Yan Han (ORCID: https://orcid.org/0000-0002-2041-3115)
- Meng Yu (ORCID: https://orcid.org/0009-0000-4988-8571)
- Jiangwei Lu (ORCID: https://orcid.org/0000-0002-7031-1811)
Institutions
- Shanghai University (CN)
- Tongji University (CN)
- Shanghai Innovative Research Center of Traditional Chinese Medicine (CN)
- Shanghai Skin Disease Hospital (CN)
Publication Details
- Journal
- Materials Today Bio
- Published
- 2025-10-12
- DOI
- https://doi.org/10.1016/j.mtbio.2025.102409
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00